Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China

BACKGROUND: Cell-free fetal DNA (cffDNA) has opened up new approaches for non-invasive prenatal testing (NIPT), and it is often used as the second-tier test for high-risk pregnant women in detecting trisomy (T) 21, T18, and T13 after serum biochemistry screening. This study aims to discuss the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanhui, Liu, Hailiang, He, Yi, Xu, Wanfang, Ma, Qiulin, He, Yuzhen, Lei, Wei, Chen, Guoquan, He, Zheng, Huang, Jiayi, Liu, Jianan, Liu, Yuanru, Huang, Quanfei, Yu, Fubing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275506/
https://www.ncbi.nlm.nih.gov/pubmed/32503639
http://dx.doi.org/10.1186/s40246-020-00268-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275506/
https://www.ncbi.nlm.nih.gov/pubmed/32503639
http://dx.doi.org/10.1186/s40246-020-00268-2

Ejemplares similares